Proactive Investors | Imugene and Kincell Bio form manufacturing and process development partnership
Proactive Investors | Imugene expands bile tract cancer study as patient shows complete response during MAST trial phase
Proactive Investors | Imugene shines at AACR with promising cancer therapy results from VAXINIA and HER-Vaxx
Proactive Investors | Imugene granted China patent for Oncolytic Virotherapy CF33
Proactive Investors | Imugene has VAXINIA technology selected for presentation at Cholangiocarcinoma Foundation conference
Proactive Investors | Imugene with Proactive at ASX Small and Mid Cap Conference
Small Caps | Imugene’s onCARlytics clears Phase 1 milestone in solid tumour therapy trial
Proactive Investors | Imugene progresses onCARlytics solid tumour trial to combination arm
Gen Bio | Biotech around the World: The Low-Down on the Land Down Under
State of the Company Address
Small Caps | Imugene doses first patient in onCARlytics trial targeting cancer with novel approach
Proactive Investors | Imugene’s Phase 1 onCARlytics clinical trial doses first patient in intravenous monotherapy arm
7 News Australia | Australian company Imugene; saving lives using a cancer eating virus
Small Caps | CEO Leslie Chong joins Small Caps to discuss the progress of the Phase 1 MAST trial of our novel cancer-killing virus CF33-hNIS – known as VAXINIA.
The West Australian (Saturday Edition) | Big hopes for cancer vaccines
Proactive Investors | CEO Leslie Chong joins Proactive in the studio to discuss the results from the Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA).
Proactive Investors | Imugene plans Phase 1 VAXINIA MAST trial expansion to target bile duct cancer
Proactive Investors | Imugene presents CF33-hNIS oncolytic virus study details at ASCO-GI Cancers Symposium
Proactive Investors | Imugene receives positive early results, including a 'complete response', in Phase 1 VAXINIA study
Small Caps | Imugene reports positive outcomes in novel virus trial against advanced cancers
STOCKHEAD | ASX Health Stocks: Imugene gains on positive early signs from Phase 1 trial
Kalkine Media | How far have Imugene’s (ASX: IMU) four novel platforms progressed in the fight against cancer?
Biotech Daily | Dr Boreham’s Crucible: Imugene
STOCKHEAD | Imugene: We need to talk about bloody cancer, and then kill it
Cancer vaccines: 10 biotech companies that have changed the game | A kind of immunotherapy, cancer vaccines have been around since the link between human papillomavirus (HPV) and cancer was discovered in the 1980s. For the prevention of cancers – cervical, vaginal, vulvar and anal cancers – caused by the virus, vaccines were developed, and later approved by the Food and Drug Administration (FDA).
April 10, 2023
THE AUSTRALIAN BUSINESS REVIEW | Imugene drug aimed at crushing cancer advances to human trials, sending its shares soaring
January 9, 2023
Newsweek | Human Injected With Cancer-killing Virus Vaxinia
May 23, 2022
The Australian | Imugene rises as chairman reassures rattled biotechnology firm’s shareholders
May 23, 2022
The Australian | Imugene soars after partnership to 'kill' cancer
November 1, 2021
The Age | ‘Groundbreaking approach’: Imugene deal looks to smash solid tumours
August 5, 2021
BioSpace | Imugene Cancer Vaccine Displays Promise in Gastric Tumors, Mid-Stage Data Shows
July 8, 2021
The Sydney Morning Herald | Cancer biotech Imugene calls on Australia to boost local research
June 16, 2021
ABC’s ‘The Business’ | Australia's leading daily business and finance show, bringing you up to date on market moves, economic trends and the forces affecting business big and small. Presented by Kathryn Robinson (Mon-Wed) and Alicia Barry (Thu).
May 26, 2021
May 19, 2021
Australian Financial Review - Imugene pens global patent licensing deal with LA-based research centre
May 18, 2021
Life Science Leader | Special Issue - Industry Outlook 2021
December 2020
Drug Target Review | Cancer-killing virus could improve precision medicine
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
December 2, 2020
Genetic Engineering & Biotechnology News | Oncolytic Virus Activates Immune System against Colon Cancer
December 2, 2020
BioWorld | Australia’s Imugene shows positive overall survival in ongoing phase II gastric cancer trial.
November 24, 2020
Pharma in Focus - Australia | Local biotechs hit milestones. Local biotech Imugene will begin the first human trials for its checkpoint inhibitor PD1-Vaxx for treatment of non-small cell lung cancer (NSCLC).
July 15, 2020
OncologyCentral | AACR20: translating oncolytic viruses into the clinic, an interview with Yuman Fong
April 29, 2020
SKY NEWS | Cancer treatment based on cowpox moves to clinical trials
February 29, 2020
Life Science Leader | A Global Biotech Player From Down Under
January 31, 2020
thepharmaletter | Eligible Imugene thinking ahead to ‘actively developing a BD department’
January 24, 2020
7NEWS SYDNEY | CF33 virus hailed as next step towards cancer cure.
November 8, 2019
6PR RADIO | Featuring Professor Yuman Fong discussing Imugene’s Oncolytic Virus CF33.
November 8, 2019
The Daily Telegraph Sydney | HOLY COW POX! VIRUS’ CURE CLUE
November 8, 2019
NEWS.COM.AU & SKY NEWS | Human trials to begin next year using a virus to kill cancer.
An Australian company has engineered a new virus based on cowpox that is able to kill every known type of cancer. Now they are ready for human trials.
November 8, 2019
FRONTIERS | Featuring Imugene’s SAB member Professor Pravin Kaumaya from Ohio State University
November 2019
STOCKHEAD | Dr Boreham’s Crucible: Has Imugene now got the assets it needs to fast-track an acquisition?
July 29, 2019
Next Biotech | IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking
July 25, 2019
The Australian BUSINESS REVIEW: Imugene buys cancer-fighting virus
July 17, 2019
BioWorld | Aussie immuno-oncology firm Imugene bolsters pipeline with oncolytic virus acquisition
July 17, 2019
MicroCap Review Magazine: Profiled Company - Imugene Limited, An Emerging Leader in Cancer Immuno-Oncology.
April 2019
OHIO STATE Oncology Update: Novel Anticancer Vaccine Shows Promise in Phase I Study - featuring our Scientific Advisory Board Member Professor Pravin Kaumaya, PhD.
March 26, 2019
Your Money - Chairman Paul Hopper interviewed on Trading Day.
January 7, 2019
Fierce Biotech - Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
December 17, 2018
SMALL CAPS - Imugene’s Phase 1b HER-Vaxx cancer trial meets endpoints, reports positive results
December 17, 2018
STOCKHEAD - Imugene’s gastric cancer drug clears first safety hurdles
December 17, 2018
next BIOTECH - Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
November 13, 2018
The Australian Financial Review - Why it’ll pay to be more open to biotech investment opportunities
July 31, 2018
The Sydney Morning Herald - Cancer-fighter Imugene looking to spark interest of big pharma
July 2, 2018
The Australian Financial Review - Imugene to raise $20m, fund trials at Ohio State University, Mayo Clinic
June 6, 2018
The Australian - Biotech entrepreneur Hopper brings companies to life
May 14, 2018
The Australian Financial Review - New thinking answers call of progress
April 7, 2017
The Australian Business Review - Imugene CEO Leslie Chong: meet the unicorn leading the cancer fight
March 5, 2017
The Sydney Morning Herald - Breakthrough for local biotech as an influential backer emerges
March 3, 2017
Life Scientist - Imugene candidate increases cancer-fighting antibodies
April 20, 2017
Bionity.com - HER-Vaxx Re-formation shows dramatic ten-fold increase in Antibodies and early onset of response
April 22, 2017
Global Health and Travel - Cancer Vaccines, The New Wave of Immune System-Based Oncology
April 2015
Proactive Investors - Imugene meets heavy demand in capital raising for HER-Vaxx
December 9, 2014
Proactive Investors - HER-Vaxx peptides demonstrate high level of activity
December 1, 2014
Life Scientist - Imugene Engages Mymetics to Manufacture HER-Vaxx Cancer Immunotherapy
July 16, 2014
Life Scientist - Imugene picks peptide manufacturer for HER-Vaxx
May 28, 2014
Proactive Investors - Imugene to be granted patent for cancer vaccine in Israel
March 24, 2014
Life Scientist - Imugene kicks off IND process for HER-Vaxx
March 18, 2014